Back to Search
Start Over
Ocular and systemic pharmacokinetics of brimonidine and brinzolamide after topical administration in rabbits: comparison between fixed-combination and single-drug formulations.
- Source :
-
Current eye research [Curr Eye Res] 2021 Mar; Vol. 46 (3), pp. 380-386. Date of Electronic Publication: 2020 Aug 12. - Publication Year :
- 2021
-
Abstract
- Aim: The aim of this study was to compare the ocular and systemic absorption of brimonidine (BMD) and brinzolamide (BZM) in rabbits after the topical administration of a fixed-combination ophthalmic suspension of 0.1% BMD tartrate and 1% BZM (FCBB) with that after the administration of the respective single-drug formulations.<br />Materials and Methods: Ocular and systemic drug absorption was estimated by determining BMD and BZM concentrations in the aqueous humor, retina/choroid, vitreous body, and blood/plasma by liquid chromatography/tandem mass spectrometry after the administration of FCBB, 0.1% BMD tartrate ophthalmic solution (0.1% BMD), or 1% BZM ophthalmic suspension (1% BZM) to rabbits.<br />Results: In concomitant administration, instilling 0.1% BMD and 1% BZM successively without interval lowered aqueous humor concentrations of both drugs compared to those observed with a 5-min interval. After FCBB administration, BMD and BZM concentrations in the aqueous humor were comparable with those observed after the administration of 0.1% BMD and 1% BZM, whereas BMD concentrations in posterior ocular tissues were equal to or higher than those observed after 0.1% BMD. Plasma BMD concentrations following the administration of FCBB were 0.8-fold lower than those after 0.1% BMD; no remarkable differences were observed in blood BZM concentrations for both formulations.<br />Conclusions: FCBB achieved drug distribution in the aqueous humor and systemic exposure that were comparable to those for the single-drug formulations. The viscosity of FCBB may increase BMD distribution in the retina/choroid. The administration interval affects ocular drug absorption with the concomitant administration of 0.1% BMD and 1% BZM, which can be overcome by using the fixed-combination of both drugs.
- Subjects :
- Administration, Topical
Adrenergic alpha-2 Receptor Agonists administration & dosage
Adrenergic alpha-2 Receptor Agonists pharmacokinetics
Animals
Aqueous Humor drug effects
Brimonidine Tartrate administration & dosage
Carbonic Anhydrase Inhibitors administration & dosage
Carbonic Anhydrase Inhibitors pharmacokinetics
Chromatography, High Pressure Liquid
Disease Models, Animal
Drug Compounding
Drug Therapy, Combination
Glaucoma metabolism
Male
Ophthalmic Solutions
Rabbits
Sulfonamides administration & dosage
Tandem Mass Spectrometry
Thiazines administration & dosage
Vitreous Body drug effects
Aqueous Humor metabolism
Brimonidine Tartrate pharmacokinetics
Glaucoma drug therapy
Sulfonamides pharmacokinetics
Thiazines pharmacokinetics
Vitreous Body metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1460-2202
- Volume :
- 46
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Current eye research
- Publication Type :
- Academic Journal
- Accession number :
- 32706598
- Full Text :
- https://doi.org/10.1080/02713683.2020.1800046